Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement.
Polymorphic HLA-DQ (DC/MB) determinants appeared to be not expressed on human hematopoietic progenitor cells (HPC), using several murine monoclonal and human polyclonal antibodies in a complement-dependent cytotoxicity (CDC) assay. Since mature HLA-DR-positive malignant lymphoma cells prove to be HLA-DQ positive, an attempt was made to remove clonogenic neoplastic DQwl-positive B cells selectively from DQwl-positive marrow samples without affecting hematopoietic progenitor cells. Using a combination of a clonogenic tumor cell assay, an HPC culture assay, and a mixed-tumor-cell-HPC culture assay, selective elimination of more than 98% of clonogenic neoplastic cells from tumor-cell-contaminated bone marrow suspensions was achieved with monoclonal anti-DQ antibodies and complement without depletion of HPC. These results indicate that anti-HLA-DQ antibodies can be used in autologous bone marrow transplantation to deplete the bone marrow cell suspension of DQ-positive malignant cells.
J H
JH
Falkenburg
W E
WE
Fibbe
W F
WF
Veenhof
F
F
Koning
G
G
van Eeden
P J
PJ
Voogt
J
J
Jansen
D000911:Antibodies, Monoclonal; D001402:B-Lymphocytes / Q000276:immunology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002460:Cell Line; D003165:Complement System Proteins; D003601:Cytotoxicity Tests, Immunologic; D000939:Epitopes / Q000276:immunology; D005453:Fluorescence; D006098:Granulocytes / Q000166:cytology; D006683:HLA-DQ Antigens; D006412:Hematopoietic Stem Cells / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D009000:Monocytes / Q000166:cytology; D009374:Neoplasms, Experimental / Q000473:pathology; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D000939:Epitopes; D006683:HLA-DQ Antigens; D000949:Histocompatibility Antigens Class II; D003165:Complement System Proteins